289 related articles for article (PubMed ID: 9096192)
1. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin.
Hoogkamp-Korstanje JA; Dirks-Go SI; Kabel P; Manson WL; Stobberingh EE; Vreede RW; Davies BI
J Antimicrob Chemother; 1997 Mar; 39(3):411-4. PubMed ID: 9096192
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance.
Richard MP; Aguado AG; Mattina R; Marre R
J Antimicrob Chemother; 1998 Feb; 41(2):207-14. PubMed ID: 9533462
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin.
Pontani D; Washton H; Bouchillon S; Johnson J
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):413-9. PubMed ID: 9758284
[TBL] [Abstract][Full Text] [Related]
4. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.
Blondeau JM; Suter M; Borsos S
J Antimicrob Chemother; 1999 Mar; 43 Suppl A():25-30. PubMed ID: 10225568
[TBL] [Abstract][Full Text] [Related]
5. Exacerbation of COPD: amoxicillin + clavulanic acid in vitro activity vs S. pneumoniae, H. influenzae and M. catarrhalis.
Beghi G; Legnani D; De Bartolo A; Pagani N; Lusco G
J Chemother; 1995 Nov; 7 Suppl 4():61-2. PubMed ID: 8904109
[No Abstract] [Full Text] [Related]
6. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
Ballow CH; Jones RN; Johnson DM; Deinhart JA; Schentag JJ
Diagn Microbiol Infect Dis; 1997 Nov; 29(3):173-86. PubMed ID: 9401810
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens.
Crokaert F; Aoun M; Duchateau V; Grenier P; Vandermies A; Klastersky J
Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):696-8. PubMed ID: 8894585
[No Abstract] [Full Text] [Related]
8. In vitro activity of tosufloxacin (A-60969) and clarithromycin (A-56268, TE-031) against resistant Haemophilus influenzae, Streptococcus pneumoniae and Branhamella catarrhalis isolates.
Bryan JP; Waters C; Sheffield J; Wagner KF
Eur J Clin Microbiol Infect Dis; 1990 May; 9(5):361-5. PubMed ID: 2142647
[TBL] [Abstract][Full Text] [Related]
9. The Viriato Study: update of antimicrobial susceptibility data of bacterial pathogens from community-acquired respiratory tract infections in Portugal in 2003 and 2004.
Melo-Cristino J; Santos L; Ramirez M;
Rev Port Pneumol; 2006; 12(1):9-30. PubMed ID: 16572254
[TBL] [Abstract][Full Text] [Related]
10. Bactericidal kinetics and postantibiotic effect of sparfloxacin against selected species of respiratory pathogens.
Speciale A; Blandino G; Nicolosi VM; Siracusa V; Caccamo F
J Chemother; 1995 Dec; 7(6):530-4. PubMed ID: 8667038
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
[TBL] [Abstract][Full Text] [Related]
12. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.
Thornsberry C; Ogilvie P; Kahn J; Mauriz Y
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):249-57. PubMed ID: 9458982
[TBL] [Abstract][Full Text] [Related]
13. [Serotype distribution and drug resistance of
Tian HL; Shi W; Zhou HF; Yuan L; Yao KH; Rexiati D; Xu AM
Zhonghua Er Ke Za Zhi; 2018 Apr; 56(4):279-283. PubMed ID: 29614568
[No Abstract] [Full Text] [Related]
14. [In vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens].
Prado V; Giangrieco M; Durán C; Ojeda A; van Flaskamp R
Rev Med Chil; 2000 Dec; 128(12):1319-26. PubMed ID: 11227240
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility of recently isolated respiratory tract pathogens to minocycline and comparable antibiotics. A multicentre study.
Verbist L; Dhoore F
Acta Clin Belg; 1994; 49(6):268-73. PubMed ID: 7871933
[TBL] [Abstract][Full Text] [Related]
16. In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci.
Wootton M; Bowker KE; Janowska A; Holt HA; MacGowan AP
J Antimicrob Chemother; 1999 Oct; 44(4):445-53. PubMed ID: 10588304
[TBL] [Abstract][Full Text] [Related]
17. Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.
Dorai-John T; Thomson CJ; Amyes SG
J Chemother; 2002 Feb; 14(1):19-24. PubMed ID: 11892894
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of telithromycin compared with macrolides and fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
Küçükbasmaci O; Gönüllü N; Aktaş Z; Gürol D; Berkiten R
Int J Antimicrob Agents; 2003 Nov; 22(5):497-501. PubMed ID: 14602368
[TBL] [Abstract][Full Text] [Related]
19. In-vitro activity of levofloxacin, a new fluoroquinolone: evaluation against Haemophilus influenzae and Moraxella catarrhalis.
Kitzis MD; Goldstein FW; Miegi M; Acar JF
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():21-6. PubMed ID: 10404333
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001.
Jones ME; Blosser-Middleton RS; Critchley IA; Karlowsky JA; Thornsberry C; Sahm DF
Clin Microbiol Infect; 2003 Jul; 9(7):590-9. PubMed ID: 12925097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]